Symbols / GBIO
GBIO Chart
About
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 35.98M |
| Enterprise Value | -27.55M | Income | -62.63M | Sales | 15.27M |
| Book/sh | 7.51 | Cash/sh | 13.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | 115 | IPO | Jun 12, 2020 |
| P/E | — | Forward P/E | -3.99 | PEG | — |
| P/S | 2.36 | P/B | 0.71 | P/C | — |
| EV/EBITDA | 0.36 | EV/Sales | -1.80 | Quick Ratio | 4.28 |
| Current Ratio | 4.44 | Debt/Eq | 51.61 | LT Debt/Eq | — |
| EPS (ttm) | -9.37 | EPS next Y | -1.34 | EPS Growth | — |
| Revenue Growth | -78.90% | Earnings | 2025-11-05 16:00 | ROA | -27.39% |
| ROE | -80.81% | ROIC | — | Gross Margin | -212.17% |
| Oper. Margin | -20.20% | Profit Margin | 0.00% | Shs Outstand | 6.74M |
| Shs Float | 4.19M | Short Float | 0.04% | Short Ratio | 0.03 |
| Short Interest | — | 52W High | 7.52 | 52W Low | 3.00 |
| Beta | 2.01 | Avg Volume | 83.32K | Volume | 551.92K |
| Target Price | — | Recom | None | Prev Close | $5.34 |
| Price | $5.34 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$5.34
Latest analyst target
3. DCF / Fair value
$-107.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.34
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | up | Wedbush | Neutral → Outperform | $6 |
| 2025-12-16 | down | Jefferies | Buy → Hold | $5 |
| 2025-08-18 | main | Canaccord Genuity | Buy → Buy | $10 |
| 2025-08-13 | reit | Needham | Buy → Buy | $15 |
| 2025-08-13 | down | Wedbush | Outperform → Neutral | $7 |
| 2025-05-08 | reit | Needham | Buy → Buy | $8 |
| 2025-04-10 | reit | Needham | Buy → Buy | $8 |
| 2025-03-17 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2025-03-14 | reit | Citizens Capital Markets | Market Perform → Market Perform | — |
| 2025-03-14 | reit | Needham | Buy → Buy | $8 |
| 2025-01-08 | main | Needham | Buy → Buy | $8 |
| 2024-10-23 | reit | Needham | Buy → Buy | $10 |
| 2024-08-08 | reit | Wedbush | Outperform → Outperform | $5 |
| 2024-08-08 | reit | Needham | Buy → Buy | $10 |
| 2024-05-14 | reit | Needham | Buy → Buy | $10 |
| 2024-05-14 | reit | Wedbush | Outperform → Outperform | $5 |
| 2024-04-10 | reit | Needham | Buy → Buy | $10 |
| 2024-03-07 | reit | Wedbush | Outperform → Outperform | $5 |
| 2024-03-07 | main | Needham | Buy → Buy | $10 |
| 2023-11-10 | main | Wedbush | Outperform → Outperform | $9 |
- Generation Bio (NASDAQ: GBIO) agrees to $4.29 sale to XOMA Royalty plus CVR - Stock Titan Mon, 15 Dec 2025 08
- GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders - Business Wire Mon, 15 Dec 2025 08
- Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance ue, 12 Aug 2025 07
- XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire Mon, 15 Dec 2025 08
- Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com ue, 16 Dec 2025 08
- Generation Bio Stock Surged 31% Pre-Market Today – What’s Going On? - Stocktwits Wed, 13 Aug 2025 07
- Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders - PR Newswire Mon, 15 Dec 2025 08
- XOMA Completes Acquisition and Delisting of Generation Bio - TipRanks Mon, 09 Feb 2026 08
- XOMA to Acquire Generation Bio (GBIO) in Strategic Merger - GuruFocus Mon, 15 Dec 2025 08
- Generation Bio CEO Resignation and Leadership Transition - The Globe and Mail hu, 23 Oct 2025 07
- Generation Bio's T Cell Delivery Success Leads to Strategic Review as Company Cuts 90% of Workforce - Stock Titan ue, 12 Aug 2025 07
- Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance Wed, 07 May 2025 07
- Generation Bio stock rating reiterated at Market Perform by Citizens - Investing.com UK Wed, 17 Dec 2025 08
- Generation Bio Announces Merger with XOMA Royalty - TipRanks Mon, 15 Dec 2025 08
- Satellos taps ex-Generation Bio COO to steer Duchenne trial plans - Stock Titan hu, 29 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1582 | — | — | MCDONOUGH CAMERON GEOFFREY | Director | — | 2026-02-02 00:00:00 | D | nan |
| 1 | 1673 | — | — | HOWZE YALONDA | Chief Executive Officer | — | 2026-02-02 00:00:00 | D | nan |
| 2 | 235 | — | — | CONWAY KEVIN JOHN | Chief Financial Officer | — | 2026-02-02 00:00:00 | D | nan |
| 3 | 395 | — | — | MCDONOUGH CAMERON GEOFFREY | Director | — | 2026-01-15 00:00:00 | D | nan |
| 4 | 335 | — | — | HOWZE YALONDA | Officer | — | 2026-01-15 00:00:00 | D | nan |
| 5 | 59 | — | — | CONWAY KEVIN JOHN | Chief Financial Officer | — | 2026-01-15 00:00:00 | D | nan |
| 6 | 659 | — | — | MCDONOUGH CAMERON GEOFFREY | Director | — | 2025-10-31 00:00:00 | D | nan |
| 7 | 527 | — | — | MCDONOUGH CAMERON GEOFFREY | Chief Executive Officer | — | 2025-10-15 00:00:00 | D | nan |
| 8 | 334 | — | — | HOWZE YALONDA | Officer | — | 2025-10-15 00:00:00 | D | nan |
| 9 | 159 | — | — | PAONE ANTOINETTE D | Chief Operating Officer | — | 2025-10-15 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.06M | -133.30M | -136.05M | -114.57M |
| TotalUnusualItems | -63.20M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -63.20M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -131.67M | -126.61M | -136.64M | -119.15M |
| ReconciledDepreciation | 4.93M | 5.26M | 5.13M | 4.53M |
| EBITDA | -74.26M | -133.30M | -136.05M | -114.57M |
| EBIT | -79.19M | -138.56M | -141.18M | -119.10M |
| NetInterestIncome | 10.72M | 11.95M | 4.54M | -50.00K |
| InterestExpense | 50.00K | |||
| InterestIncome | 10.72M | 11.95M | 4.54M | |
| NormalizedIncome | -68.47M | -126.61M | -136.64M | -119.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -131.67M | -126.61M | -136.64M | -119.15M |
| TotalExpenses | 99.08M | 144.47M | 141.18M | 119.10M |
| TotalOperatingIncomeAsReported | -142.39M | -138.56M | -141.18M | -119.10M |
| DilutedAverageShares | 6.66M | 6.45M | 5.81M | 5.63M |
| BasicAverageShares | 6.66M | 6.45M | 5.81M | 5.63M |
| DilutedEPS | -19.80 | -19.60 | -23.50 | -21.20 |
| BasicEPS | -19.80 | -19.60 | -23.50 | -21.20 |
| DilutedNIAvailtoComStockholders | -131.67M | -126.61M | -136.64M | -119.15M |
| NetIncomeCommonStockholders | -131.67M | -126.61M | -136.64M | -119.15M |
| NetIncome | -131.67M | -126.61M | -136.64M | -119.15M |
| NetIncomeIncludingNoncontrollingInterests | -131.67M | -126.61M | -136.64M | -119.15M |
| NetIncomeContinuousOperations | -131.67M | -126.61M | -136.64M | -119.15M |
| PretaxIncome | -131.67M | -126.61M | -136.64M | -119.15M |
| OtherIncomeExpense | -63.20M | |||
| SpecialIncomeCharges | -63.20M | 0.00 | 0.00 | |
| OtherSpecialCharges | 63.20M | |||
| NetNonOperatingInterestIncomeExpense | 10.72M | 11.95M | 4.54M | -50.00K |
| TotalOtherFinanceCost | 50.00K | |||
| InterestExpenseNonOperating | 50.00K | |||
| InterestIncomeNonOperating | 10.72M | 11.95M | 4.54M | |
| OperatingIncome | -79.19M | -138.56M | -141.18M | -119.10M |
| OperatingExpense | 99.08M | 144.47M | 141.18M | 119.10M |
| ResearchAndDevelopment | 61.30M | 93.62M | 96.72M | 85.25M |
| SellingGeneralAndAdministration | 37.78M | 50.85M | 44.46M | 33.85M |
| GeneralAndAdministrativeExpense | 37.78M | 50.85M | 44.46M | 33.85M |
| OtherGandA | 16.73M | 20.50M | 16.95M | 11.70M |
| SalariesAndWages | 21.05M | 30.35M | 27.51M | 22.15M |
| TotalRevenue | 19.89M | 5.90M | 0.00 | 0.00 |
| OperatingRevenue | 19.89M | 5.90M | 0.00 | 0.00 |
| Line Item | 2021-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 1.11K | |||
| OrdinarySharesNumber | 6.70M | 6.62M | 5.95M | 5.70M |
| ShareIssued | 6.70M | 6.62M | 5.95M | 5.70M |
| TotalDebt | 93.56M | 97.89M | 81.71M | 80.83M |
| TangibleBookValue | 86.20M | 203.13M | 282.49M | 381.75M |
| InvestedCapital | 86.20M | 203.13M | 282.49M | 381.75M |
| WorkingCapital | 157.85M | 232.70M | 267.87M | 360.38M |
| NetTangibleAssets | 86.20M | 203.13M | 282.49M | 381.75M |
| CapitalLeaseObligations | 93.56M | 97.89M | 81.71M | 80.83M |
| CommonStockEquity | 86.20M | 203.13M | 282.49M | 381.75M |
| TotalCapitalization | 86.20M | 203.13M | 282.49M | 381.75M |
| TotalEquityGrossMinorityInterest | 86.20M | 203.13M | 282.49M | 381.75M |
| StockholdersEquity | 86.20M | 203.13M | 282.49M | 381.75M |
| GainsLossesNotAffectingRetainedEarnings | 159.00K | 274.00K | -83.00K | 0.00 |
| OtherEquityAdjustments | 159.00K | 274.00K | -83.00K | |
| RetainedEarnings | -703.04M | -571.38M | -444.76M | -308.13M |
| AdditionalPaidInCapital | 789.08M | 774.22M | 727.34M | 689.87M |
| CapitalStock | 7.00K | 7.00K | 6.00K | 6.00K |
| CommonStock | 7.00K | 7.00K | 6.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 144.99M | 171.63M | 93.77M | 95.03M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 109.94M | 131.72M | 74.62M | 76.22M |
| OtherNonCurrentLiabilities | 223.00K | |||
| NonCurrentDeferredLiabilities | 29.16M | 41.94M | 0.00 | 0.00 |
| NonCurrentDeferredRevenue | 29.16M | 41.94M | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 80.55M | 89.77M | 74.62M | 76.22M |
| LongTermCapitalLeaseObligation | 80.55M | 89.77M | 74.62M | 76.22M |
| CurrentLiabilities | 35.05M | 39.91M | 19.15M | 18.81M |
| OtherCurrentLiabilities | 2.66M | 406.00K | 426.00K | 676.00K |
| CurrentDeferredLiabilities | 10.58M | 12.92M | 0.00 | 0.00 |
| CurrentDeferredRevenue | 10.58M | 12.92M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 13.01M | 8.12M | 7.09M | 4.61M |
| CurrentCapitalLeaseObligation | 13.01M | 8.12M | 7.09M | 4.61M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.97M | 13.21M | 7.97M | 7.58M |
| PayablesAndAccruedExpenses | 2.83M | 5.26M | 3.67M | 5.95M |
| CurrentAccruedExpenses | 1.43M | 2.92M | 3.01M | 3.92M |
| Payables | 1.41M | 2.35M | 662.00K | 2.02M |
| AccountsPayable | 1.41M | 2.35M | 662.00K | 2.02M |
| TotalAssets | 231.20M | 374.76M | 376.26M | 476.77M |
| TotalNonCurrentAssets | 38.29M | 102.14M | 89.25M | 97.58M |
| OtherNonCurrentAssets | 2.59M | 6.39M | 7.39M | 6.09M |
| NonCurrentPrepaidAssets | 100.00K | 100.00K | ||
| NonCurrentDeferredAssets | 433.00K | 434.00K | 461.00K | |
| NetPPE | 35.60M | 95.65M | 81.42M | 91.03M |
| AccumulatedDepreciation | -22.91M | -19.70M | -14.54M | -10.02M |
| GrossPPE | 58.51M | 115.35M | 95.96M | 101.05M |
| Leases | 20.91M | 20.86M | 20.79M | 17.37M |
| ConstructionInProgress | 192.00K | 7.03M | 13.00K | 3.75M |
| OtherProperties | 34.66M | 84.71M | 72.83M | 77.97M |
| MachineryFurnitureEquipment | 2.75M | 2.74M | 2.33M | 1.95M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 192.90M | 272.62M | 287.02M | 379.19M |
| OtherCurrentAssets | 2.42M | 290.00K | 259.00K | 4.04M |
| AssetsHeldForSaleCurrent | 163.00K | 0.00 | ||
| PrepaidAssets | 3.54M | 3.82M | 7.01M | 4.04M |
| Receivables | 1.56M | 4.15M | 660.00K | 0.00 |
| OtherReceivables | 1.22M | 3.96M | 395.00K | |
| AccruedInterestReceivable | 335.00K | 188.00K | 265.00K | |
| AccountsReceivable | 395.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 185.22M | 264.36M | 279.09M | 375.14M |
| OtherShortTermInvestments | 108.92M | 197.92M | 185.92M | 0.00 |
| CashAndCashEquivalents | 76.30M | 66.45M | 93.17M | 375.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -90.96M | -60.14M | -111.25M | -97.78M |
| IssuanceOfCapitalStock | 0.00 | 36.00M | 0.00 | 211.88M |
| CapitalExpenditure | -2.40M | -7.40M | -8.80M | -5.96M |
| EndCashPosition | 78.45M | 72.24M | 98.86M | 380.84M |
| BeginningCashPosition | 72.24M | 98.86M | 380.84M | 64.94M |
| ChangesInCash | 6.22M | -26.63M | -281.97M | 315.90M |
| FinancingCashFlow | 250.00K | 35.82M | 12.99M | 214.67M |
| CashFlowFromContinuingFinancingActivities | 250.00K | 35.82M | 629.00K | 214.67M |
| NetOtherFinancingCharges | -186.00K | -729.00K | 11.73M | -955.00K |
| ProceedsFromStockOptionExercised | 436.00K | 546.00K | 1.26M | 3.75M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 36.00M | 0.00 | 211.88M |
| CommonStockIssuance | 0.00 | 36.00M | 0.00 | 211.88M |
| InvestingCashFlow | 94.53M | -9.70M | -192.51M | 193.05M |
| CashFlowFromContinuingInvestingActivities | 94.53M | -9.70M | -192.51M | 193.05M |
| NetInvestmentPurchaseAndSale | 96.73M | -2.30M | -183.71M | 198.90M |
| SaleOfInvestment | 232.00M | 403.00M | 140.00M | 198.90M |
| PurchaseOfInvestment | -135.27M | -405.30M | -323.71M | 0.00 |
| NetPPEPurchaseAndSale | -2.21M | -7.40M | -8.80M | -5.85M |
| SaleOfPPE | 196.00K | 0.00 | 0.00 | 105.00K |
| PurchaseOfPPE | -2.40M | -7.40M | -8.80M | -5.96M |
| OperatingCashFlow | -88.56M | -52.74M | -102.45M | -91.82M |
| CashFlowFromContinuingOperatingActivities | -88.56M | -52.74M | -102.45M | -91.82M |
| ChangeInWorkingCapital | -31.43M | 53.54M | 1.05M | 4.17M |
| ChangeInOtherWorkingCapital | -15.12M | 41.60M | ||
| ChangeInOtherCurrentLiabilities | -8.62M | 16.19M | 881.00K | -3.70M |
| ChangeInOtherCurrentAssets | 3.44M | -9.21M | 4.64M | 2.92M |
| ChangeInPayablesAndAccruedExpense | -8.34M | 5.37M | -591.00K | 3.59M |
| ChangeInAccruedExpense | -7.96M | 4.29M | 795.00K | 1.83M |
| ChangeInPayable | -386.00K | 1.09M | -1.39M | 1.76M |
| ChangeInAccountPayable | -386.00K | 1.09M | -1.39M | 1.76M |
| ChangeInPrepaidAssets | -1.56M | 3.16M | -3.49M | 1.37M |
| ChangeInReceivables | -1.22M | -3.56M | -395.00K | 0.00 |
| OtherNonCashItems | 62.59M | 27.00K | 41.00K | |
| StockBasedCompensation | 14.61M | 24.34M | 24.45M | 17.86M |
| AssetImpairmentCharge | 259.00K | 39.00K | 5.81M | 0.00 |
| AmortizationOfSecurities | -7.85M | -9.34M | -2.29M | 529.00K |
| DepreciationAmortizationDepletion | 4.93M | 5.26M | 5.13M | 4.53M |
| DepreciationAndAmortization | 4.93M | 5.26M | 5.13M | 4.53M |
| OperatingGainsLosses | 27.00K | 41.00K | 237.00K | |
| GainLossOnSaleOfPPE | 27.00K | 41.00K | 237.00K | |
| NetIncomeFromContinuingOperations | -131.67M | -126.61M | -136.64M | -119.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|